Marinus Pharma (MRNS) Reports In-Line Q4 EPS

Marinus Pharma (NASDAQ: MRNS) reported Q4 EPS of ($0.77), in-line with the analyst estimate of ($0.77). Revenue for the quarter came in at $1.52 million versus the consensus estimate of $3.46 million.

For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Aecon wins $1.7B share of Alberta power plant contract
• RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform